{"id":1500,"date":"2015-10-28T15:00:02","date_gmt":"2015-10-28T14:00:02","guid":{"rendered":"http:\/\/intervacc.se\/?p=1500\/"},"modified":"2017-02-20T15:21:16","modified_gmt":"2017-02-20T14:21:16","slug":"intervacc-signs-agreement-optimization-manufacturing","status":"publish","type":"post","link":"https:\/\/intervacc.se\/en\/intervacc-signs-agreement-optimization-manufacturing\/","title":{"rendered":"Intervacc signs agreement for optimization of manufacturing"},"content":{"rendered":"<div class=\"preamble\">Intervacc is pleased to announce that an agreement has now been signed with PX\u00b4Therapeutics, Grenoble, France, for process optimization of Strangvac. PX\u00b4Therapeutics, a subsidiary of Aguettant pharmaceutical group, has the experience, facilities and personnel to produce recombinant proteins from E. coli in compliance with GMP.<\/div>\n<p>The aim is to obtain a more efficient and cost effective production of Strangvac<sup>\u00ae<\/sup>, which is composed of three recombinant proteins. Initial work on optimization has already begun and Intervacc foresees a smooth transfer of production technology and analytical procedures associated with the manufacturing process.<\/p>\n<p><a href=\"http:\/\/www.px-therapeutics.com\/\" target=\"_blank\"><img loading=\"lazy\" class=\"alignleft wp-image-1487 size-full\" src=\"http:\/\/intervacc.se\/wp-content\/uploads\/2017\/02\/logo_pxt.png\" alt=\"PX-Therapeutics\" width=\"312\" height=\"68\" srcset=\"https:\/\/intervacc.se\/wp-content\/uploads\/2017\/02\/logo_pxt.png 312w, https:\/\/intervacc.se\/wp-content\/uploads\/2017\/02\/logo_pxt-300x65.png 300w\" sizes=\"(max-width: 312px) 100vw, 312px\" \/><\/a> <a href=\"http:\/\/www.aguettant.com\/\" target=\"_blank\"><img loading=\"lazy\" class=\"alignright wp-image-1488 size-full\" src=\"http:\/\/intervacc.se\/wp-content\/uploads\/2017\/02\/aguettant.png\" alt=\"Aguettant logo\" width=\"125\" height=\"152\" \/><\/a><\/p>\n<p style=\"clear: both;\">\n","protected":false},"excerpt":{"rendered":"<p>Intervacc is pleased to announce that an agreement has now been signed with PX\u00b4Therapeutics, Grenoble, France, for process optimization of [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false},"categories":[25],"tags":[],"_links":{"self":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/posts\/1500"}],"collection":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/comments?post=1500"}],"version-history":[{"count":1,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/posts\/1500\/revisions"}],"predecessor-version":[{"id":1502,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/posts\/1500\/revisions\/1502"}],"wp:attachment":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/media?parent=1500"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/categories?post=1500"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/tags?post=1500"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}